Sunakiment vs tezepelumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
Sunakiment
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
Reported efficacy
Part A and Part B: Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)); Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Terminal rate constant (λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)): Primary outcome, adverse events in Part A (healthy adults) and Part B (asthma): acceptable safety profile, low incidence of treatment-induced antidrug antibodies (part A n=1; part B n=2); safety outcome, no formal efficacy test. The other registered primaries are pharmacokinetic. Secondary outcome, FeNO change vs placebo at day 28 in Part B: 23% reduction with 8 mg (P=.037). (not_applicable)
Result source: NCT05110976
tezepelumab · Tezspire
Marketed by AstraZeneca and partners
NCT03347279 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.
Next expected readout: November 2026 · NCT06705764 (registry estimate)
Reported efficacy
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.); Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL (From randomisation to Study Week 52.): Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39) (met)
Result source: NCT03347279
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sunakiment | tezepelumab |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | 0.9 vs 2.1−1.2 vs placeboNCT033472796 other results
|
| Trough FEV1, change | —Not reported | —Not posted · NCT05280418 |
| ACQ-5, change | —Not reported | —Not posted · NCT05280418 |
| OCS dose reduction | —Not reported | —Not posted · NCT05280418 |
Severe exacerbations, annualised rate
- Sunakiment
- —Not reported
- tezepelumab
- 0.9 vs 2.1−1.2 vs placeboNCT03347279
6 other results
- 0.2 vs 0.7 NCT02054130
- 0.2 vs 0.7 NCT02054130
- 0.3 vs 0.7 NCT02054130
- 0.0 vs 0.1 NCT02054130
- 0.0 vs 0.1 NCT02054130
- 0.0 vs 0.1 NCT02054130
Trough FEV1, change
- Sunakiment
- —Not reported
- tezepelumab
- —Not posted · NCT05280418
ACQ-5, change
- Sunakiment
- —Not reported
- tezepelumab
- —Not posted · NCT05280418
OCS dose reduction
- Sunakiment
- —Not reported
- tezepelumab
- —Not posted · NCT05280418
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Sunakiment: no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Sunakiment: 0 of 4 rows · tezepelumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tezepelumab |
|---|---|
| Dropout rate | 3%210mg Q4Wa NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3 show 19 more results0.9%210 mg Q4W NCT03968978 · Phase 3 · Asthma · phase 3 8.1% NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3 7.5%210mg Q4W NCT03927157 · Phase 3 10.9%210 mg NCT02054130 · Phase 2 16.1%280 mg NCT02054130 · Phase 2 8%70 mg NCT02054130 · Phase 2 10.8% NCT05329194 · Phase 4 · registry result, not featured evidence 8.4% NCT05274815 · Phase 3 · registry result, not featured evidence 2.9% NCT05062759 · Phase 3 · registry result, not featured evidence —NAVIGATOR Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence 3%NAVIGATOR Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence —SOURCE Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence 8.1%SOURCE Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence 0%210 mg Q4W NCT04048343 · Phase 3 · registry result, not featured evidence 1.7%210 mg Q4W NCT03688074 · Phase 2 · registry result, not featured evidence 0% NCT04673630 · Phase 1 · registry result, not featured evidence 0%140 mg NCT02512900 · Phase 1 · registry result, not featured evidence 0%140 mg NCT02512900 · Phase 1 · registry result, not featured evidence 12.5%700 mg NCT01405963 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —210mg Q4Wa NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3 show 19 more results0.9%210 mg Q4W NCT03968978 · Phase 3 · Asthma · phase 3 — NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3 0.5%210mg Q4W NCT03927157 · Phase 3 —210 mg NCT02054130 · Phase 2 —280 mg NCT02054130 · Phase 2 —70 mg NCT02054130 · Phase 2 — NCT05329194 · Phase 4 · registry result, not featured evidence 0.3% NCT05274815 · Phase 3 · registry result, not featured evidence — NCT05062759 · Phase 3 · registry result, not featured evidence —NAVIGATOR Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence —NAVIGATOR Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence —SOURCE Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence —SOURCE Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence —210 mg Q4W NCT04048343 · Phase 3 · registry result, not featured evidence 0%210 mg Q4W NCT03688074 · Phase 2 · registry result, not featured evidence — NCT04673630 · Phase 1 · registry result, not featured evidence —140 mg NCT02512900 · Phase 1 · registry result, not featured evidence —140 mg NCT02512900 · Phase 1 · registry result, not featured evidence 6.3%700 mg NCT01405963 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 9.8%210mg Q4Wa NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3 show 19 more results4.5%210 mg Q4W NCT03968978 · Phase 3 · Asthma · phase 3 16.2% NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3 8%210mg Q4W NCT03927157 · Phase 3 9.5%210 mg NCT02054130 · Phase 2 13.1%280 mg NCT02054130 · Phase 2 12.3%70 mg NCT02054130 · Phase 2 10.8% NCT05329194 · Phase 4 · registry result, not featured evidence 9.4% NCT05274815 · Phase 3 · registry result, not featured evidence 0% NCT05062759 · Phase 3 · registry result, not featured evidence 8.3%NAVIGATOR Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence 15.5%NAVIGATOR Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence 12.5%SOURCE Pbo to Teze NCT03706079 · Phase 3 · registry result, not featured evidence 24.3%SOURCE Rand Teze NCT03706079 · Phase 3 · registry result, not featured evidence 6.2%210 mg Q4W NCT04048343 · Phase 3 · registry result, not featured evidence 5.1%210 mg Q4W NCT03688074 · Phase 2 · registry result, not featured evidence 0% NCT04673630 · Phase 1 · registry result, not featured evidence 0%140 mg NCT02512900 · Phase 1 · registry result, not featured evidence 0%140 mg NCT02512900 · Phase 1 · registry result, not featured evidence 0%700 mg NCT01405963 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 210mg Q4Wa nasopharyngitis 21.4% (placebo 21.5%) upper respiratory tract infection 11% (placebo 16.6%) headache 8.1% (placebo 8.5%) NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3 show 19 more results210 mg Q4W nasopharyngitis 10.8% upper respiratory tract infection 8.1% asthma 5.4% NCT03968978 · Phase 3 · Asthma · phase 3 nasopharyngitis 16.2% (placebo 25%) upper respiratory tract infection 12.2% (placebo 10.5%) asthma 8.1% (placebo 10.5%) NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3 210mg Q4W upper respiratory tract infection 35.3% (placebo 34.2%) covid-19 14.4% (placebo 12.6%) suspected covid-19 8% (placebo 12.6%) NCT03927157 · Phase 3 210 mg asthma 16.8% (placebo 34.1%) nasopharyngitis 13.9% (placebo 11.6%) headache 8% (placebo 4.3%) NCT02054130 · Phase 2 280 mg asthma 25.5% (placebo 34.1%) nasopharyngitis 10.9% (placebo 11.6%) bronchitis 6.6% (placebo 5.1%) NCT02054130 · Phase 2 70 mg asthma 22.5% (placebo 34.1%) nasopharyngitis 13.8% (placebo 11.6%) bronchitis 5.1% (placebo 5.1%) NCT02054130 · Phase 2 alopecia 0.3% intervertebral disc degeneration 0.3% ligament sprain 0.3% NCT05329194 · Phase 4 · registry result, not featured evidence adrenal insufficiency 0.3% atrial fibrillation 0.3% insomnia 0.3% NCT05274815 · Phase 3 · registry result, not featured evidence covid-19 22.9% (placebo 22.9%) acute sinusitis 8.6% (placebo 0%) skin laceration 5.7% (placebo 0%) NCT05062759 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.2% (placebo 23.4%) headache 6.3% (placebo 10.2%) covid-19 4.9% (placebo 1.5%) NCT03706079 · Phase 3 · registry result, not featured evidence nasopharyngitis 24.6% (placebo 23.4%) upper respiratory tract infection 13.6% (placebo 17.1%) headache 11% (placebo 10.2%) NCT03706079 · Phase 3 · registry result, not featured evidence nasopharyngitis 21.9% (placebo 23.4%) covid-19 12.5% (placebo 1.5%) hypertension 12.5% (placebo 4.9%) NCT03706079 · Phase 3 · registry result, not featured evidence nasopharyngitis 24.3% (placebo 23.4%) upper respiratory tract infection 16.2% (placebo 17.1%) bronchitis 12.2% (placebo 7.3%) NCT03706079 · Phase 3 · registry result, not featured evidence 210 mg Q4W nasopharyngitis 20% pharyngitis 9.2% back pain 4.6% NCT04048343 · Phase 3 · registry result, not featured evidence 210 mg Q4W nasopharyngitis 37.3% (placebo 36.8%) post procedural complication 18.6% (placebo 17.5%) cough 10.2% (placebo 7%) NCT03688074 · Phase 2 · registry result, not featured evidence covid-19 11.1% headache 11.1% nasopharyngitis 11.1% NCT04673630 · Phase 1 · registry result, not featured evidence 140 mg bronchitis 18.2% nasopharyngitis 18.2% pyrexia 9.1% NCT02512900 · Phase 1 · registry result, not featured evidence 140 mg acute sinusitis 10% contusion 10% gastritis 10% NCT02512900 · Phase 1 · registry result, not featured evidence 700 mg nasopharyngitis 25% (placebo 26.7%) oropharyngeal pain 18.8% (placebo 6.7%) asthma 12.5% (placebo 6.7%) NCT01405963 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 17 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tezepelumab
show 2 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 70 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sunakiment's landscape · tezepelumab's landscape